Saturday, September 21, 2024

Suven’s depression drug shows promise in phase 2a trial; stocks trade flat

Must read


Suven Life Sciences announced positive topline results from its Phase 2a proof-of-concept study for Ropanicant (SUVN-911), a novel treatment for moderate to severe major depressive disorder (MDD). The open-label study, involving 41 patients across 10 US sites, demonstrated statistically significant improvements in depressive symptoms as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).

The shares of Suven Life Sciences Limited were trading flat at ₹158.01 on the NSE at 12.45 pm.

Patients treated with Ropanicant showed mean MADRS score improvements of 5.9-13.4 points on day 7, and 10.4-12.7 points on day 14 across different doses. The drug was generally well tolerated, with no serious adverse events reported.

Suven plans to advance Ropanicant to a double-blind, placebo-controlled Phase 2b study in early 2025. The company will present the topline data at the Neuroscience-2024 conference in Chicago this October.

Ropanicant is being developed to address the limitations of existing MDD treatments, potentially offering rapid onset of action without sexual dysfunction side effects.







Source link

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article